BD's Q3 Earnings Beat Estimates, Margins Up 5.1%, Revenues Rise 10.4% YoY

Becton Dickinson and Company (BDX) reported Q3 EPS of $3.68, up 5.1% YoY and beating the Zacks Consensus Estimate by 7.6%. Revenues increased 10.4% YoY to $5.51 billion, surpassing the consensus estimate by 0.5%. The company's BD Medical and BD Interventional segments drove the top-line improvement. Shares gained nearly 9.8% in pre-market trading.

Becton Dickinson and Company (BDX) reported its third-quarter (Q3) fiscal 2025 financial results, showcasing robust revenue growth and improved earnings per share (EPS). The company reported a 10.4% year-over-year (YoY) increase in revenue to $5.51 billion, surpassing the Zacks Consensus Estimate by 0.5%. The reported EPS of $3.68 was up 5.1% YoY, beating the Zacks Consensus Estimate by 7.6%. The company's BD Medical and BD Interventional segments drove the top-line improvement [1].

The company also raised its full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an increase of $0.18 to 9.4% growth at the midpoint. This guidance reflects strong Q3 operating performance and incremental investments in selling and marketing in Q4. The organic revenue growth guidance was reaffirmed at 3.0% to 3.5%. The company expects the impact of translational foreign currency to be an increase of approximately $10 million to revenue year over year and about neutral to adjusted EPS for the full fiscal year [1].

The Q3 results were driven by strong performance across multiple segments. The BD Medical segment, which includes the Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring business units, reported organic revenue growth of 3.2%. The BD Interventional segment, comprising Surgery, Peripheral Intervention, and Urology & Critical Care units, showed mid single-digit growth. The BD Life Sciences segment, which includes Specimen Management, Diagnostic Solutions, and Biosciences business units, experienced low single-digit growth, partially offset by declines in Diagnostic Solutions and Biosciences [1].

Shares of BDX gained nearly 9.8% in pre-market trading following the announcement, reflecting investor confidence in the company's performance and future prospects. The company also announced plans to complete the remaining $250 million of a $1 billion share buyback commitment by the end of fiscal 2025 [1].

References:
[1] https://investors.bd.com/news-events/press-releases/detail/899/bd-reports-third-quarter-fiscal-2025-financial-results